kernel
Kernel 1.0

Posted on 05.07.08 to . Grab the feed. No comments yet. Add your thoughts or trackback from your own site.

3-hydroxy-3-methylglutaryl coenzyme A reductase (3-hydroxy-3-methylglutaryl-CoA reductase, putative). predicted to bind 3 ligands [SIM 114 117]

UniPort id: Q9Y0F3 [L. major]
Target keywords: ; Antineoplastic Agents; Anticholesteremic Agents; Oxidoreductase.; NADP; Hydroxymethylglutaryl-CoA Reductase Inhibitors; HMG-CoA Reductase Inhibitors; Q9Y0F3; Antilipemic Agents
Do you consider this target suitable for drug discovery: 0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this post.


Binding site prediction to approved drugs (need help reading this page?):

PDB Template Model Ligand Exact SupStr SubStr Similar
+
 1hw8D 100.00/100.00 1dqaA 52.00/1.64 LmjF30.3190.1.pdb 78.26/100.00 114 DB00175 DB00641 DB00175 DB00227

Shwon ligand 114 COMPACTIN expanded from 1hw8D to template 1dqaA used for building a 3D model of LmjF30.3190.1.pdb. Donwload the coordinates data/Q9Y0F3/Q9Y0F3.114.3.pdb

DB00227 Lovastatin

Small Molecule; Approved

Drug categories:

  • Antineoplastic Agents
  • Anticholesteremic Agents
  • HMG-CoA Reductase Inhibitors
Drug indication:

For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia; For primary prevention of coronary heart disease
DB00175 Pravastatin

Small Molecule; Approved

Drug categories:

  • Anticholesteremic Agents
  • HMG-CoA Reductase Inhibitors
Drug indication:

For the treatment of hypercholesterolemia to reduce the risk of myocardial infarction.
DB00641 Simvastatin

Small Molecule; Approved

Drug categories:

  • Anticholesteremic Agents
  • Antilipemic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug indication:

For the treatment of hypercholesterolemia.
+
 1hwkD 100.00/100.00 1dqaA 52.00/1.64 LmjF30.3190.1.pdb 84.00/100.00 117 DB01076 DB01076 DB01076 DB01076

Shwon ligand 117 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOICACID expanded from 1hwkD to template 1dqaA used for building a 3D model of LmjF30.3190.1.pdb. Donwload the coordinates data/Q9Y0F3/Q9Y0F3.117.3.pdb

DB01076 Atorvastatin

Small Molecule; Approved

Drug categories:

  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug indication:

For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia.
+
 1hw9D 100.00/100.00 1dqaA 52.00/1.64 LmjF30.3190.1.pdb 78.26/100.00 SIM DB00641 DB00175 DB00227

Shwon ligand SIM SIMVASTATIN expanded from 1hw9D to template 1dqaA used for building a 3D model of LmjF30.3190.1.pdb. Donwload the coordinates data/Q9Y0F3/Q9Y0F3.SIM.1.pdb

DB00227 Lovastatin

Small Molecule; Approved

Drug categories:

  • Antineoplastic Agents
  • Anticholesteremic Agents
  • HMG-CoA Reductase Inhibitors
Drug indication:

For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia; For primary prevention of coronary heart disease
DB00175 Pravastatin

Small Molecule; Approved

Drug categories:

  • Anticholesteremic Agents
  • HMG-CoA Reductase Inhibitors
Drug indication:

For the treatment of hypercholesterolemia to reduce the risk of myocardial infarction.
DB00641 Simvastatin

Small Molecule; Approved

Drug categories:

  • Anticholesteremic Agents
  • Antilipemic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug indication:

For the treatment of hypercholesterolemia.

SPEAK / ADD YOUR COMMENT
Comments are moderated.

You must be logged in to post a comment.